Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

Equality Impact Assessment (Guidance development) (PDF 159 KB)

Register of interests (PDF 137 KB)

Final draft guidance: 2

Final appraisal document 2 (PDF 326 KB)

Committee papers (PDF 1.23 MB)

Public committee slides (PDF 510 KB)

Appeal

ABC : Appeal letter (MSWord 213 KB)

FBC : Appeal letter (MSWord 103 KB)

MSD : Appeal letter (MSWord 110 KB)

ABC : Scrutiny letter (MSWord 57 KB)

FBC : Scrutiny letter (MSWord 59 KB)

MSD : Scrutiny letter (MSWord 61 KB)

ABC : Response to scrutiny letter (MSWord 212 KB)

FBC : Response to scrutiny letter (MSWord 20 KB)

MSD : Response to scrutiny letter (MSWord 82 KB)

MSD : Final scrutiny letter (MSWord 60 KB)

MSD : Response to final scrutiny letter (MSWord 66 KB)

MSD : Written submission (MSWord 67 KB)

MSD : NICE's final response (MSWord 80 KB)

Appeal decision (MSWord 63 KB)

Final draft guidance

Final appraisal document (PDF 289 KB)

Committee papers (PDF 1.53 MB)

Public committee slides (PDF 569 KB)

Draft guidance

Appraisal consultation document (online commenting)

Committee papers (PDF 3.31 MB)

Public committee slides (PDF 1.03 MB)

Appraisal consultation document (PDF version) (PDF 319 KB)

Final scope (PDF 226 KB)

Final stakeholder list (PDF 260 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 247 KB)